Pulmonary Delivery of Inhalable Sustained Release Nanocomposites Microparticles Encapsulating Osimertinib for Non-Small Cell Lung Cancer Therapy
Authors:
- Iman M. AlfagihIAIman M. Alfagih
- Alanood AlmurshediAAAlanood Almurshedi
- Basmah AldosariBABasmah Aldosari
- Bushra AlquadeibBABushra Alquadeib
- Baraa HajjarBHBaraa Hajjar
- Hafsa ElwaliHEHafsa Elwali
- Hadeel AltukhaimHAHadeel Altukhaim
- Eman AlzahraniEAEman Alzahrani
- Sara AlhumaidanSASara Alhumaidan
- Ghaida AlharbiGAGhaida Alharbi
Open Access
- 21 January 2026
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (1) , 134
Abstract
Background/Objective: Osimertinib (OSI) is a third-generation tyrosine kinase inhibitor approved for non-small cell lung cancer (NSCLC) therapy. OSI is administered orally; this route limits the amount of OSI reaching the tumor in the lungs and is associated with serious systemic toxicity. This study aimed to develop a dry powder inhalable formulation to provide tumor-targeted delivery and minimize systemic toxicity. To the best of our knowledge, this is the first study to prepare and evaluate a dry powder inhalation formulation of OSI. Methods: Chitosan-coated PLGA nanoparticles (PLGA-C NPs) encapsulating OSI were prepared using a single emulsion-solvent evaporation technique. PLGA-C NPs were assembled into respirable nanocomposite microparticles (NCMPs) via spray drying with L-leucine as a carrier. PLGA-C NPs were characterized for particle size, zeta-potential, encapsulation efficiency, and in vitro efficacy in A-549 cell line. NCMPs were evaluated for solid-state properties, aerosolization performance, stability and in vitro release. Results: PLGA-C NPs exhibited a particle size of 145.18 ± 3.0 nm, high encapsulation efficiency and a positive zeta potential. In vitro studies demonstrated a 3.6-fold reduction in IC50 compared to free OSI, superior antimigratory effects and enhanced cell cycle arrest. Solid-state characterization of NCMPs demonstrated drug encapsulation in the polymer without chemical interaction. NCMPs exhibited excellent aerosolization (mass median aerodynamic diameter of 1.09 ± 0.23 μm, fine particle fraction of 73.48 ± 8.6%) and sustained drug release (61.76 ± 3.9% at 24 h). Stability studies confirmed the physicochemical stability integrity. Conclusions: These findings suggest that this novel dry powder inhalable OSI formulation may improve therapeutic outcomes while reducing systemic toxicity.Keywords
This publication has 40 references indexed in Scilit:
- Advancements in Particle Engineering for Inhalation Delivery of Small Molecules and BiotherapeuticsPharmaceutical Research, 2022
- Pulmonary delivery of osimertinib liposomes for non-small cell lung cancer treatment: formulation development and in vitro evaluationDrug Delivery and Translational Research, 2021
- Afatinib-loaded inhalable PLGA nanoparticles for localized therapy of non-small cell lung cancer (NSCLC)—development and in-vitro efficacyDrug Delivery and Translational Research, 2021
- Adjuvant Osimertinib: A New Standard of CareThe Oncologist, 2020
- Novel Silibinin Loaded Chitosan-Coated PLGA/PCL Nanoparticles Based Inhalation Formulations with Improved Cytotoxicity and Bioavailability for Lung CancerBioNanoScience, 2020
- Targeting EGFR in Lung Cancer: Current Standards and DevelopmentsDrugs, 2018
- Patient Experience of Symptoms and Side Effects when Treated with Osimertinib for Advanced Non-Small-Cell Lung Cancer: A Qualitative Interview SubstudyThe Patient - Patient-Centered Outcomes Research, 2017
- Synthesis of a trimannosylated-equipped archaeal diether lipid for the development of novel glycoliposomesCarbohydrate Research, 2016
- Pulmonary Delivery of Proteins Using Nanocomposite MicrocarriersJournal of Pharmaceutical Sciences, 2015
- Bovine Serum Albumin Adsorbed PGA-co-PDL Nanocarriers for Vaccine Delivery via Dry Powder InhalationPharmaceutical Research, 2014